Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViPOR in Relapsed/Refractory B-cell Lymphoma
NCT03223610Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2018
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in B cell lymphoma (4 arms), sponsored by National Cancer Institute. Primary endpoint: Number and grade of adverse events at 22 days. Started Feb 2018; status: recruiting.
02
Drugs
venetoclax
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03223610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223610.